Castagna A - Search Results

1

Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.

Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M. Menzo S, et al. Among authors: castagna a. New Microbiol. 2004 Apr;27(2 Suppl 1):51-61. New Microbiol. 2004. PMID: 15646065

2

The introduction of the fusion inhibitors in the HAART-regimens.

Hasson H, Castagna A, Clementi M, Menzo S, Danise A, Lazzarin A. Hasson H, et al. Among authors: castagna a. New Microbiol. 2004 Apr;27(2 Suppl 1):11-6. New Microbiol. 2004. PMID: 15646060 Clinical Trial.

3

Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.

Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, Boeri E, Nozza S, Cossarin F, Galli A, Gianotti N, Castagna A, Lazzarin A, Clementi M. Canducci F, et al. Among authors: castagna a. Clin Microbiol Infect. 2011 Jun;17(6):928-34. doi: 10.1111/j.1469-0691.2010.03375.x. Epub 2010 Nov 5. Clin Microbiol Infect. 2011. PMID: 20854427 Free article.

4

Longitudinal evaluation of occult hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption.

Bagaglio S, Bianchi G, Danise A, Porrino L, Uberti-Foppa C, Lazzarin A, Castagna A, Morsica G. Bagaglio S, et al. Among authors: castagna a. Infection. 2011 Apr;39(2):121-6. doi: 10.1007/s15010-011-0093-9. Epub 2011 Mar 22. Infection. 2011. PMID: 21424854

5

Etravirine for the treatment of HIV infection.

Seminari E, Castagna A, Lazzarin A. Seminari E, et al. Among authors: castagna a. Expert Rev Anti Infect Ther. 2008 Aug;6(4):427-33. doi: 10.1586/14787210.6.4.427. Expert Rev Anti Infect Ther. 2008. PMID: 18662109 Review.

6

Long-term response in patients receiving HAART including nelfinavir: experience from two Italian centers.

Castagna A, Danise A, Giudici B, Lazzarin A, Castelli F, Paraninfo G, Carosi G, Carriero PL. Castagna A, et al. J Chemother. 2002 Apr;14(2):189-93. doi: 10.1179/joc.2002.14.2.189. J Chemother. 2002. PMID: 12017376

7

Relation between CD4 cell counts and HIV RNA levels at onset of opportunistic infections.

Brambilla AM, Castagna A, Nocita B, Hasson H, Boeri E, Veglia F, Lazzarin A. Brambilla AM, et al. Among authors: castagna a. J Acquir Immune Defic Syndr. 2001 May 1;27(1):44-8. doi: 10.1097/00126334-200105010-00008. J Acquir Immune Defic Syndr. 2001. PMID: 11404519

8

HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients.

Gianotti N, Canducci F, Galli L, Cossarini F, Salpietro S, Poli A, Nozza S, Spagnuolo V, Clementi M, Sampaolo M, Ceresola ER, Racca S, Lazzarin A, Castagna A. Gianotti N, et al. Among authors: castagna a. Clin Microbiol Infect. 2015 Jan;21(1):103.e7-103.e10. doi: 10.1016/j.cmi.2014.08.004. Epub 2014 Oct 13. Clin Microbiol Infect. 2015. PMID: 25636935 Free article.

9

Raltegravir in treatment naive patients.

Cossarini F, Castagna A, Lazzarin A. Cossarini F, et al. Among authors: castagna a. Eur J Med Res. 2009 Nov 24;14 Suppl 3(Suppl 3):22-9. doi: 10.1186/2047-783x-14-s3-22. Eur J Med Res. 2009. PMID: 19959413 Free PMC article. Review.

10

Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.

Seminari E, Castagna A, Soldarini A, Galli L, Fusetti G, Dorigatti F, Hasson H, Danise A, Guffanti M, Lazzarin A, Rubinacci A. Seminari E, et al. Among authors: castagna a. HIV Med. 2005 May;6(3):145-50. doi: 10.1111/j.1468-1293.2005.00278.x. HIV Med. 2005. PMID: 15876279 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,092 results

Search Page